SK Capital cracked a business to maintain and strengthen its financial presence and drive growth and expansion

Announcement

SK Capital Partners, LP, a well-known New York-based private investment entity focused on the life sciences, ingredients sectors and speciality materials, has declared that its syndicate has entered the deal to invest in Swixx BioPharma AG to elevate the Company’s future stage of global expansion and growth. The investment is worth around EUR €1.5 billion. The Swixx is the champion in commercialising and promoting the specific services committed to providing life-changing and innovative medications to the unreached markets and individuals.

The Swixx Co-Founders, Stuart Swanson and Petr Nemec and Swixx’s CEO and CFO, Jean-Michel Lespinasse and Petr Pipal, will be continuing with their noteworthy ownership stakes in Swixx as a part of the money inflow and outflow. The previous institutional investors HBM Healthcare Investments, a Swiss ticked investment company a Merieux Equity Partners and a promising healthcare market. It’s a known healthcare specialised investment firm that will also retain as a promising shareholder in Swixx.

Divided roles and responsibilities among the experts and leaders

The Rothschild & Co. is delivering as an independent individual financial advisor to SK Capital. The legal counsel will be Bar & Karrer and Kirkland & Ellis. The KPMG LLP is an advisory to IT due diligence, financial, compliance and tax. Alongside, the ClearView Healthcare Partners advises on marketise due diligence. Whereas, the Ares Credit funds delivered the promising debt financing in contribution to these transactions.

The Lead Financial Advisor to the Swixx BioPharma and its shareholders is Jefferies, who will act and align based on the correlation with the transaction. Walder Wyss was hired as a legal advisor to Swixx BioPharma, and Centerview Partners worked as a financial advisor to the same firm. For this deal, EY delivered its best advisory on tax, legal vendor due diligence (VDD) services, compliance and financial, whereas BCG backed with the commercial VDD.

Managing Director at SK Capital, Aaron Davenport, said, “We are thrilled to collaborate with Swixx BioPharma, as it shares a similar promise to modernise healthcare and improve patient outcomes. Our investment underlines the confidence in Swixx’s leadership and its potential to serve the commendable sustainable business growth throughout the diverse markets.”

The Swixx’s CEO, Jean-Michel, commented, “This collaboration represents a crucial and important turning point for Swixx, which has gathered both expertise and capital to boost the growth.”